Recurrent primary peritoneal high grade serous adenocarcinoma
Clinical trials for Recurrent primary peritoneal high grade serous adenocarcinoma explained in plain language.
Never miss a new study
Get alerted when new Recurrent primary peritoneal high grade serous adenocarcinoma trials appear
Sign up with your email to follow new studies for Recurrent primary peritoneal high grade serous adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine combo shows promise in ovarian cancer fight
Disease control OngoingThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRαDC) with an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells. The trial …
Matched conditions: RECURRENT PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
Immune-Boosting drug combo takes on Hard-to-Treat ovarian cancer
Disease control OngoingThis pilot study tests two drugs—pembrolizumab (an immunotherapy) and lenvatinib (a targeted enzyme blocker)—in women with platinum-resistant high-grade serous ovarian, fallopian tube, or peritoneal cancer. The goal is to see how these drugs, given alone and together, change immu…
Matched conditions: RECURRENT PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 women will receive one of s…
Matched conditions: RECURRENT PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC